Cases from the Clinic(ians): Case-Based Panel Discussion

Size: px
Start display at page:

Download "Cases from the Clinic(ians): Case-Based Panel Discussion"

Transcription

1 Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: Learning Objectives After attending this presentation, learners will be able to: Know when to initiate therapy for acute HIV infection Define the timing of discontinuation of primary prophylaxis Describe the biology of HIV in the setting of ARV therapy Slide 3 of 50 Slide 4 of 50 Should I treat patients with acute seroconversion syndrome, and if so, when and with what ARV therapy? Page 1 of 17

2 Case 1 Slide 5 of yo man presents with mononucleosis-like illness Febrile, faint rash on chest, pharyngeal edema, diffuse lymphadenopathy Combo Ab/Ag Test: HIV Ab Negative P24 Ag Positive Slide 6 of 50 At this point you would order confirmatory HIV RNA, genotypic resistance test, and: 1. Hold ARV Rx until lab tests return 2. Start ARV Rx with 2 nucs and an NNRTI 3. Start ARV Rx with 2 nucs and a boosted PI 4. Start ARV Rx with 2 nucs and an STII (integrase inhibitor) 5. Not give ARV Rx until otherwise indicated Slide 7 of 50 Natural History and Laboratory Staging of HIV Infection Eclipse Phase I II III IV V VI v RNA+ (Fiebig, AIDS 2003) Western blot +/- Western blot + (p31-) Western + (p31+) Keele et al., PNAS 2008 Page 2 of 17

3 CROI 2014: Acute Infection Slide 8 of 50 Sigmoid Biopsies: Significantly lower frequency of Th17 cells was observed in FIII compared to FI/ II (Median 7.1% vs. 13.2%, p=0.03) (Schuetz Abstract 77) Initiation of ART at very early stages of infection (Fiebig I) impeded seroconversion to anti-hiv antibody. Initiation of ART at Fiebig II-V delayed evolution of serological markers (Manak Abst 395) Extremely Early Initiation of ART (~Day10) HIV RNA/DNA tests have been negative, including those performed in colorectal biopsy Samples enriched for total CD4+ T cells and CD4+ T cell subsets (Tn, Tcm, Ttm, Tem) from leukapheresis were also negative for HIV RNA and DNA (Cheret Abst 398) Slide 9 of Slide 9 of 52 Slide 10 of 52 Slide 10 of 50 Page 3 of 17

4 Slide 11 of 52 Slide 11 of 50 Slide 12 of 52 Slide 12 of 50 Slide 13 of 52 Slide 13 of 50 Page 4 of 17

5 Slide 14 of Viral Load T 1/2 = 1.1 days Slide 14 of Weeks Slide 15 of 50 What do I do for patients who have virologic success but a poor CD4 count response? Case 2 Slide 16 of yo female started on TDF / FTC / ATZ / rit 3 years ago Initial: Now: HIV RNA 78,000 c/ml CD4 count 80 cells/ul HIV RNA < 50 c/ml (persistently) CD4 167 cells/ul She is tolerating the regimen well Page 5 of 17

6 At this point you would: Slide 17 of Continue her current ARV Rx 2. Change her ARV Rx to 2 nucs and an NNRTI 3. Change her ARV Rx to 2 nucs and a different boosted PI 4. Change her ARV Rx to 2 nucs and an STII (integrase inhibitor) 5. Change her ARV Rx to an STII and a different boosted PI 6. Something else What is Immunologic Failure? 6 weeks 3 months 2 years 3 years Slide 18 of 50 Slide 19 of 50 Can I stop PCP prophylaxis in a patient with a good virologic response but immunologic failure? Page 6 of 17

7 Case 3 Slide 20 of yo female started on TDF / FTC /ATZ / rit 3 years ago Initial: Now: HIV RNA 78,000 c/ml CD4 count 80 cells/ul HIV RNA < 50 c/ml (persistently) CD4 167 cells/ul (CD4 % = 12%) She remains on TMP/ SMX primary prophylaxis, one DS tablet daily and tolerating it well At this point you would: Slide 21 of Continue her current TMP/SMX Rx 2. Change her Rx to 1 DS tablet every other day 3. Stop all PCP prophylaxis 4. Call Dr. Friedland Slide 22 of 50 Page 7 of 17

8 Conclusions: The virus is Evil: Replication: Bad Suppression: Good CD4 count cutoffs for PCP prophylaxis established prior to effective ARV Rx Slide 23 of 50 In setting where VL < 50, PCP prophylaxis can be safely stopped when CD4 > 100 cells Slide 24 of 50 In a patient with elevated lipids, do I change the antiretroviral therapy or add lipid therapy? Case 4 56 yo male started on ARV Rx many years ago (unknown resistance history) Has been through multiple regimens; now on TDF / FTC / Lop / rit Non-Smoker / Neg PMH / Neg Fam Hx for CAD Now: Slide 25 of 50 HIV RNA < 50 c/ml (persistently) CD4 560 cells/ul Cholesterol 220 mg/dl (HDL 38 / LDL 122) Triglycerides 540 mg/dl Page 8 of 17

9 At this point you would: 1. Continue her current ARV Rx 2. Change her Lop/Rit to DRV/Rit 3. Change her Lop/Rit to an SSTI 4. Start a statin 5. 1 and and and 4 8. None of the above Slide 26 of 50 Case 5 56 yo male started on ARV Rx many years ago (unknown resistance history) Has been through multiple regimens; now on TDF / FTC / DRV / rit Non-Smoker / H/o DM / Neg Fam Hx for CAD Now: Slide 27 of 50 HIV RNA < 50 c/ml (persistently) CD4 560 cells/ul Cholesterol 220 mg/dl (HDL 38 / LDL 122) Slide 28 of 50 In addition to starting a statin, you would: 1. Continue her current ARV Rx 2. Change her DRV/Rit to NNRTI 3. Change her DRV/Rit to an SSTI 4. Some other option Page 9 of 17

10 Slide 29 of 50 What is the current status of use of abacavir in a patient with CV risk factors? Case 6 56 yo male started on ARV Rx many years ago (resistance history no known PI mutations) Has been through several regimens; now on ABC / 3TC / Dolutegravir Smoker / Diabetic / + Fam Hx for CAD Now: Slide 30 of 50 HIV RNA < 50 c/ml (persistently) CD4 560 cells/ul Cholesterol 220 mg/dl (HDL 38 / LDL 122) Slide 31 of 50 In addition to starting a statin, you would: 1. Continue her current ARV Rx 2. Change her ABC/3TC to TDF/FTC 3. Change her ABC/3TC to DRV/rit 4. Some other option Page 10 of 17

11 Clinical experience with DRV/r + DTG Slide 32 of 50 There is no effect of DTG on DRV/r PK DRV/r 600/100 BID lowers DTG Cmin by 38%. This is not considered clinically significant, given the 50mg OD dose of DTG used DRV/r + integrase proof of principle: NEAT (DRV/r + RAL vs DRV/r + TDF/FTC) (CROI 2014) DRV/r + DTG + 2 Nucs was the most common combination used in the SAILING Trial (Lancet 2013, 382, ) Slide 33 of 50 What is the best initial ARV therapy for a patient with baseline CKD? Case 7 Slide 34 of yo male newly diagnosed HIV resistance assay reveals wild type virus Smoker / H/o DM / Neg Fam Hx for CAD HIV RNA 128,000 c/ml CD4 count 280 cells/ul S-creatinine 2.1 mg/dl (ecrcl = 48 cc/min) Page 11 of 17

12 What ARV regimen would you start? 1. TDF every other day, FTC, EFV 2. TDF every other day, FTC, DRV/rit 3. ABC / 3TC / EFV 4. ABC / 3TC / DRV/rit 5. ABC / 3TC / DTG 6. TDF / FTC / ELV / cobi 7. ABC / FTC / DRV/rit 8. DRV/rit / RAL 9. DRV/rit / DTG 10. Some other option Slide 35 of 50 Slide 36 of 50 What is the best way to manage chronic HBV infection in a patient with CKD? Case 8 Slide 37 of yo male newly diagnosed HIV resistance assay reveals wild type virus Smoker / H/o DM / Neg Fam Hx for CAD HIV RNA 128,000 c/ml CD4 count 280 cells/ul S-creatinine 2.1 mg/dl (ecrcl = 48 cc/min) HBsAb+ / HBsAg+ / HBeAg- Page 12 of 17

13 Slide 38 of 50 With regard to treating the HBV, what is the best approach? 1. TDF every other day in the regimen 2. FTC in the regimen (no other nuc) 3. 3TC in the regimen (no other nuc) 4. Entecavir in addition to the ARV Rx 5. Adefovir in addition to the ARV Rx 6. PEG-IFN weekly in addition to the ARV Rx for 48 weeks 7. No need to Rx for HBV in this setting 8. Some other option Slide 39 of 50 How do I best use resistance test results, especially in a patient with a baseline K65R? Case 9 56 yo male started on ARV Rx many years ago (resistance history no known PI mutations) Has been through several regimens; now on TDF / FTV / ETV Smoker / Diabetic / + Fam Hx for CAD VL Max: 240,000 c/ml / CD4 nadir 5 cells/ul Slide 40 of 50 Now: HIV RNA 1200 c/ml (confirmed) CD4 160 cells/ul Page 13 of 17

14 Slide 41 of 50 Which ARV regimen would you choose: 1. ABC / 3TC / EFV 2. ABC / 3TC / DTG 3. ABC / 3TC / DRV/ rit 4. TDF / FTC / ELV / cobi 5. TDF / FTC / EFV 6. TDF / FTC / DRV / rit 7. RAL / DRV/ rit +/- FTC 8. DTG / DRV/ rit +/- FTC 9. Another choice What ARV regimen would you use now? 1. TDF, FTC, ATZ/rit 2. TDF, FTC, DRV/rit 3. ABC / 3TC / DRV/rit 4. ABC / 3TC / DTG 5. TDF / FTC / ELV / cobi 6. TDF / ZDV / DRV/rit 7. ZDV / DRV/rit / DTG 8. DRV/rit / DTG / FTC 9. Some other option Slide 42 of 50 Slide 43 of 50 Can I simplify the ARV regimen of an ARV experienced patient who is now under virologic control? Page 14 of 17

15 Case yo male started on ARV Rx many years ago (3 class resistance by history; 184V, K103N, Y181C, D30N) Slide 44 of 50 Has been through several regimens; has been on ZDV / TDF / FTC / DRV/rit / RTG VL Max: 240,000 c/ml / CD4 nadir 5 cells/ul Now: HIV RNA <50 c/ml (for 3 years) CD4 360 cells/ul Slide 45 of 50 With regard to simplifying the regimen, you would: 1. Continue her current ARV Rx (GHWB) 2. Stop the ZDV and cont TDF/ FTC / DRV/rit / RTG 3. Stop the ZDV and cont TDF/ FTC / DRV/rit 4. Stop the ZDV and cont TDF/ FTC / RTG 5. Stop the TDF and cont ZDV/ FTC / DRV/rit / RTG 6. Some other option Slide 46 of 50 What will be the right approach for selection of initial ARV Rx when more drugs become generic? Page 15 of 17

16 Case 11 Slide 47 of yo male newly diagnosed HIV resistance assay reveals wild type virus Non-Smoker / Neg PMH/ Neg Fam Hx for CAD HIV RNA 128,000 c/ml CD4 count 280 cells/ul S-creatinine 0.9 mg/dl HBsAb+ / HBcAb- / HBsAg- What ARV regimen would you start? Slide 48 of Generic ZDV, 3TC, EFV 2. Brand TDF + Generic 3TC, EFV 3. Generic ABC + 3TC + EFV 4. Brand TDF / FTC / EFV (FDC) 5. Brand TDF / FTC / ELV / cobi (FDC) 6. Brand ABC / 3TC / DTG (FDC) 7. Some other option Patent expiration dates for HIV drugs Slide 49 of 50 The original 20 year patents for most key antiretrovirals have already expired, or will expire in the next 3-4 years. Walensky, 49 et al, Ann Int Med 158, 2013 Page 16 of 17

17 Slide 50 of 50 Patent expiration dates for HIV drugs 2012: ZDV, 3TC, d4t, ddi, SQV, NVP generic 2013: ritonavir, efavirenz, ZDV/3TC generic 2016: abacavir, LPV/r (soft-gel) 2017: atazanavir, tenofovir, darunavir 2019: etravirine, ABC/3TC 2024: TDF/FTC 2025: raltegravir 2026: TDF/FTC/EFV, TDF/FTC/RPV, dolutegravir Ref: Medecins Sans Frontieres 2013: Untangling the web of ARV price reductions Page 17 of 17

Panelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li

Panelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University

More information

Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion

Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion Slide 1 of 51 Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama

More information

HIV 101. Applications of Antiretroviral Therapy

HIV 101. Applications of Antiretroviral Therapy HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,

More information

Treating HIV in 2018 Interactive Cases From the Clinic(ians)

Treating HIV in 2018 Interactive Cases From the Clinic(ians) Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama

More information

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches

Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor

More information

Comprehensive Guideline Summary

Comprehensive Guideline Summary Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and

More information

HIV Treatment: New and Veteran Drugs Classes

HIV Treatment: New and Veteran Drugs Classes HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are

More information

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and

More information

The next generation of ART regimens

The next generation of ART regimens The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state

More information

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Pediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,

More information

Antiretroviral Treatment Strategies: Clinical Case Presentation

Antiretroviral Treatment Strategies: Clinical Case Presentation Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

What's new in the WHO ART guidelines How did markets react?

What's new in the WHO ART guidelines How did markets react? WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting

More information

Antiretroviral Therapy: What to Start

Antiretroviral Therapy: What to Start FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,

More information

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H. Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community

More information

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,

More information

Pharmacological considerations on the use of ARVs in pregnancy

Pharmacological considerations on the use of ARVs in pregnancy Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl

More information

STRIBILD (aka. The Quad Pill)

STRIBILD (aka. The Quad Pill) NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria

More information

2016 Perinatal Treatment Guidelines Update

2016 Perinatal Treatment Guidelines Update Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation

More information

HIV Treatment: State of the Art 2013

HIV Treatment: State of the Art 2013 HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial

More information

Case # 1. Case #1 (cont d)

Case # 1. Case #1 (cont d) Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic

More information

HIV - Therapy Principles

HIV - Therapy Principles HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV

More information

Rajesh T. Gandhi, M.D.

Rajesh T. Gandhi, M.D. HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000

More information

Susan L. Koletar, MD

Susan L. Koletar, MD HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen? Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is

More information

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,

More information

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily

Third Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages

More information

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi 6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie

More information

Didactic Series. CROI 2014 Update. March 27, 2014

Didactic Series. CROI 2014 Update. March 27, 2014 Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,

More information

Friday afternoon Programme

Friday afternoon Programme Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008

More information

Somnuek Sungkanuparph, M.D.

Somnuek Sungkanuparph, M.D. HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start

More information

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role

More information

What are the most promising opportunities for dose optimisation?

What are the most promising opportunities for dose optimisation? What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Update on Antiretroviral Treatment for HIV Infection 2008

Update on Antiretroviral Treatment for HIV Infection 2008 Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:

More information

Treatment of HCV in HIV/HCV Coinfection

Treatment of HCV in HIV/HCV Coinfection Treatment of HCV in HIV/HCV Coinfection Michael S. Saag, MD Associate Dean, Global Health Professor of Medicine Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama

More information

Resistance Workshop. 3rd European HIV Drug

Resistance Workshop. 3rd European HIV Drug 3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance

More information

Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents

Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

Simplifying Antiretroviral Therapy Regimens: It s not so simple

Simplifying Antiretroviral Therapy Regimens: It s not so simple Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts

More information

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral

More information

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD

More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

Antiretroviral Treatment 2014

Antiretroviral Treatment 2014 Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon

More information

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation

More information

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv

Disclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases

More information

Integrase Strand Transfer Inhibitors on the Horizon

Integrase Strand Transfer Inhibitors on the Horizon NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation

More information

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions

More information

Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses

More information

2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall

2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall 2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University

More information

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007

MDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus

More information

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

Didactic Series. Switching Regimens in the Setting of Virologic Suppression Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines

More information

Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era

Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon

More information

Clinical Management of Resistance. AMJ Wensing, MD, PhD

Clinical Management of Resistance. AMJ Wensing, MD, PhD Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More

More information

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School

Update on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in

More information

Hepatitis B Case Studies

Hepatitis B Case Studies NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No

More information

Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?

Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical

More information

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,

More information

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1 Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,

More information

INDUCTION/MAINTENANCE Clinical Case

INDUCTION/MAINTENANCE Clinical Case INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD

More information

SELECTING THE BEST ART FOR EACH PATIENT

SELECTING THE BEST ART FOR EACH PATIENT SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May

More information

Antiretroviral Drugs

Antiretroviral Drugs Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &

More information

Didactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching

Didactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University

More information

The ART of Managing Drug-Drug Interactions in Patients with HIV

The ART of Managing Drug-Drug Interactions in Patients with HIV The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe

More information

Management of NRTI Resistance

Management of NRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington

More information

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression

More information

Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa

Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults

More information

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017 Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for

More information

Criteria for Oral PrEP

Criteria for Oral PrEP Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates

More information

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo

Virological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline

More information

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question

Disclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for

More information

Dolutegravir-Rilpivirine (Juluca)

Dolutegravir-Rilpivirine (Juluca) Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL

More information

The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases

The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE

More information

Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges

Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges Update on CADO/PADO: what are the challenges in using the current guidelines and foreseen ARV revisions: opportunities and challenges Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato,

More information

ARV Consolidated Guidelines 2015

ARV Consolidated Guidelines 2015 ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical

More information

What next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute

What next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,

More information

Disclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation:

Disclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation: Disclosures Antiretroviral Therapy Initiation: From Guidelines to Practice: ART 101 Medical Management of AIDS & Hepatitis December 8, 2017 Research grant support from Gilead Sciences for ongoing work

More information

/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program

/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program /AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course

More information

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical

More information

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,

More information

Dr Andrew Ustianowski

Dr Andrew Ustianowski BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Andrew Ustianowski North Manchester General Hospital 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Clinical skills building - HIV drug resistance

Clinical skills building - HIV drug resistance Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)

More information

Outline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?

Outline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start? Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs

More information

Persistent low level viraemia on third line ART

Persistent low level viraemia on third line ART Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis

More information

Antiretroviral Therapy: Panel Discussion

Antiretroviral Therapy: Panel Discussion disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none

More information

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New

More information

CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz

CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz Question for the audience Do you think that any integrase inhibitor drug produce CNS adverse

More information

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1 MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at

More information

Unmet needs and challenges of current ART in South Africa. Michelle Moorhouse 21 Nov 2015

Unmet needs and challenges of current ART in South Africa. Michelle Moorhouse 21 Nov 2015 Unmet needs and challenges of current ART in South Africa Michelle Moorhouse 21 Nov 2015 SA Snapshot Òct 2015 6-7 million HIV-positive: 18% world total, 25% of Southern Africa 3.2 on first line ART: consume

More information

Statistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University

Statistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:

More information

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir

Supplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses

More information

Professor Jeffery Lennox

Professor Jeffery Lennox BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,

More information